VBI Selects Clinical Candidates with Potential as 1-Dose Covid Vaccines

 – VBI-2901 and VBI-2902 selected as trivalent and monovalent coronavirus vaccine candidates, respectively, for an adaptive Phase 1/2 clinical study expected to begin around year-end 2020, subject to regulatory approvals

– After one dose, compared to high-titer convalescent sera, preclinical data demonstrated 10x higher antibody binding geometric mean titer (GMT) and 4x higher neutralizing antibody GMT, with neutralizing antibody GMT increasing to 64x after a second dose

– GMP clinical manufacturing expected to begin in September 2020 at Therapure Biomanufacturing – potential to leverage capacity to support large-scale manufacturing

– VBI hosted conference call and webcast today, Wednesday, August 26 at 8:30 a.m. ET

https://seekingalpha.com/pr/17984169-vbi-vaccines-announces-preclinical-coronavirus-program-data-and-selection-of-clinical